Molecular Identification of AMY, an Alzheimer Disease Amyloid-Associated Protein

Journal of Neuropathology and Experimental Neurology

Volumn 62, Issue 11, 2003, Pages 1108-1117

  Söderberg, Linda ^d   Zhukareva, Victoria ^b   Bogdanovic, Nenad ^a   Hashimoto, Tadafumi ^c   Winblad, Bengt ^a   Iwatsubo, Takeshi ^c   Lee, Virginia M Y ^b   Trojanowski, John Q ^b   Näslund, Jan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d Novum ^*

Author keywords

Alzheimer disease; Amyloid peptide; CLAC; Collagen; Neurodegeneration; Plaques

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; PROTEIN AMY; PROTEIN CLAC; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR BIOLOGY; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION;

EID: 0242440879     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/62.11.1108     Document Type: Article

References (24)

1. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-66
2. Hardy J, Selkoe DJ. The amyloid cascade hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-56
3. Vassar R, Bennet BD, Babu-Khan S, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by transmembrane aspartic protease BACE. Science 1999;286:735-41
4. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-84
5. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-59
6. Jarrett JT, Lansbury PT. Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-58
7. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53
8. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 1996;2:864-70
9. Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid β-peptide and associated proteins. Peptides 2002;23:1343-50
10. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988;52:487-501
11. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol 1996;138:22-32
12. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-66
13. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:2892-97
14. 1-antichymotrypsin enhances Alzheimer-like pathology in amyloid precursor transgenic mice. Am J Pathol 2000;157:2003-10
15. Munson GW, Roher AE, Kuo YM, et al. SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides. Biochemistry 2000;39:16119-24
16. 1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci U S A 1995;92:2313-17
17. Schmidt ML, Lee VM-Y, Forman M, Chiu T-S, Trojanowski JQ. Monoclonal antibodies to a 100-kd protein reveal abundant Aβ-negative plaques throughout gray matter of Alzheimer's disease brains. Am J Pathol 1997;151:69-80
18. Lemere CA, Grenfell TJ, Selkoe DJ. The AMY antigen co-occurs with Aβ and follows its deposition in the amyloid plaques of Alzheimer's disease and Down syndrome. Am J Pathol 1999;155:29-37
19. Hashimoto T, Wakabayashi T, Watanabe A, et al. CLAC: A novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/ collagen XXV. EMBO J 2002;21:1524-34
20. Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-82
21. Näslund J, Thyberg J, Tjernberg LO, et al. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 1995;15:219-28
22. Schmidt ML, Saido TC, Lee VM-Y, Trojanowski JQ. Spatial relationship of AMY protein deposits and different species of Aβ peptides in amyloid plaques of the Alzheimer disease brain. J Neuropathol Exp Neurol 1999;58:1227-33
23. Lippa CF, Schmidt ML, Nee LE, et al. AMY plaques in familial AD. Neurology 2000;54:100-104
24. Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999;96:15233-38